Home » Stocks » CTLT

Catalent, Inc. (CTLT)

Stock Price: $118.28 USD -1.39 (-1.16%)
Updated Jan 21, 2021 4:00 PM EST - Market closed
Market Cap 19.48B
Revenue (ttm) 3.28B
Net Income (ttm) 249.20M
Shares Out 164.14M
EPS (ttm) 1.58
PE Ratio 74.77
Forward PE 46.08
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $118.28
Previous Close $119.67
Change ($) -1.39
Change (%) -1.16%
Day's Open 119.70
Day's Range 117.54 - 119.97
Day's Volume 580,161
52-Week Range 36.95 - 119.97

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 day ago

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene...

Investors Business Daily - 2 days ago

Catalent is forming a base and near a possible buy zone ahead of its next quarterly earnings report, expected on or around Feb. 3. The post Earnings Season Preview: Catalent Near Buy Zone With...

Zacks Investment Research - 3 days ago

Catalent (CTLT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

24/7 Wall Street - 1 week ago

Increasingly, the Wall Street firms we cover are starting to agree that while the future for the U.S.

Other stocks mentioned: CRL, FCX, NOC
Business Wire - 2 weeks ago

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell...

Zacks Investment Research - 2 weeks ago

Catalent (CTLT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

24/7 Wall Street - 3 weeks ago

As is the case every year, the major Wall Street firms we cover here at 24/7 Wall St.

Other stocks mentioned: AVTR, HCA, HOLX, GH
Zacks Investment Research - 4 weeks ago

Does Catalent (CTLT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Investors Business Daily - 1 month ago

On Friday, Catalent got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. The post Catalent Joins Rank Of Stocks With 95-Plus Composite Rating appeared first on Investor's Bus...

Benzinga - 1 month ago

Catalent Inc (NYSE: CTLT) is a “key component” of the transformation of the health care industry from pharma to biopharma, according to KeyBanc Capital Markets. The Catalent Analyst: Paul Knig...

Zacks Investment Research - 1 month ago

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).

CNBC Television - 2 months ago

Final Trades: Deere, Host Hotels, Retail & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other stocks mentioned: DE, HST, EA, XRT
Business Wire - 2 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell...

Benzinga - 2 months ago

Each week, Benzinga will examine a stock that might be considered a little under the radar. You may have never heard of the company before, but chances are you're pretty familiar with the line...

Seeking Alpha - 2 months ago

Catalent, Inc. (CTLT) CEO John Chiminski on Q1 2021 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Catalent (CTLT) delivered earnings and revenue surprises of 13.16% and 4.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 2 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell...

GlobeNewsWire - 2 months ago

REGULATED INFORMATION

Business Wire - 3 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell...

Zacks Investment Research - 4 months ago

In the due course of the S&P 400 Index's fabulous performance in the past five months, several mid-cap stocks have become large caps. We have selected six of these that carry a favorable Zacks...

Other stocks mentioned: ETSY, FBHS, GNRC, POOL, W
Investopedia - 4 months ago

Etsy (ETSY), Catalent (CTLT), and Teradyne (TER) will join the index on Sept. 21.

Other stocks mentioned: ETSY, TER
Zacks Investment Research - 4 months ago

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Catalent (CTLT).

PRNewsWire - 4 months ago

NEW YORK, Sept. 4, 2020 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriat...

Other stocks mentioned: ETSY, TER
CNBC - 4 months ago

Some Tesla investors expected the company to be included this quarter, as the company recently reported its fourth consecutive quarter of profitability. 

Other stocks mentioned: ETSY, TSLA, TER
Business Wire - 4 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc.

Seeking Alpha - 4 months ago

Catalent, Inc. (CTLT) CEO John Chiminski on Q4 2020 Results - Earnings Call Transcript

Investors Business Daily - 4 months ago

IBD Stock Of The Day Catalent has inked Covid vaccine manufacturing deals with AstraZeneca, Johnson & Johnson and Moderna, riding those contracts to record highs. It also beat Q4 goals.

GuruFocus - 4 months ago

Before the opening bell on Aug. 31, Catalent Inc. (NYSE:CTLT), a multinational corporation headquartered in Somerset, New Jersey, released its fourth-quarter financial results.

Benzinga - 4 months ago

Catalent (NYSE: CTLT) shares are trading higher on Monday after the company reported better-than-expected fourth-quarter EPS and sales results.

Zacks Investment Research - 4 months ago

Catalent (CTLT) delivered earnings and revenue surprises of 7.14% and 0.46%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 4 months ago

Shares of Catalent (NYSE:CTLT) rose 2.7% in pre-market trading after the company reported Q4 results.

Business Wire - 4 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc.

Zacks Investment Research - 4 months ago

Catalent (CTLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc.

Business Wire - 5 months ago

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc.

Seeking Alpha - 5 months ago

The Race To Erase COVID-19

Other stocks mentioned: AZN, BNTX, EBS, JNJ, LZAGY, MRNA, NVAX, PFE
Business Wire - 6 months ago

SOMERSET, N.J. & BURLINGAME, Calif.

The Motley Fool - 6 months ago

This company will make money from Moderna's COVID-19 vaccine even if Moderna doesn't.

Investopedia - 6 months ago

Bullish chart patterns suggest that the the mid-cap growth market segment is worth watching over the weeks and months ahead.

Other stocks mentioned: FDS, IJK
Zacks Investment Research - 6 months ago

Moderna (MRNA) teams up with Catalent for large-scale, commercial fill-finish manufacturing of the former's mRNA-based COVID-19 vaccine candidate.

Other stocks mentioned: MRNA
Benzinga - 6 months ago

Moderna Inc (NASDAQ: MRNA), a frontrunner in the COVID-19 vaccine race, announced a manufacturing collaboration agreement Thursday with contract development and manufacturing organization Cata...

Other stocks mentioned: MRNA
Reuters - 6 months ago

Moderna Inc said on Thursday it was partnering with contract drugmaker Catalent Inc to prepare an initial 100 million doses of its coronavirus vaccine for the United States, starting in the th...

Other stocks mentioned: MRNA
Reuters - 6 months ago

Moderna Inc said on Thursday it was partnering with contract drugmaker Catalent Inc for filling and packaging millions of doses of its experimental coronavirus vaccine to be supplied in the Un...

Other stocks mentioned: MRNA
Market Watch - 6 months ago

Shares of Moderna Inc. MRNA, +3.01% gained 2.6% in premarket trading on Thursday after the company said that Catalent Inc.

Other stocks mentioned: MRNA
Business Wire - 6 months ago

CAMBRIDGE, Mass. & SOMERSET, N.J.--(BUSINESS WIRE)--Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a n...

Other stocks mentioned: MRNA
The Motley Fool - 7 months ago

The contract manufacturer will be able to supply hundreds of millions of doses of AZD1222 starting in August.

Other stocks mentioned: AZN
The Motley Fool - 7 months ago

A combination of acquisitions and coronavirus vaccine manufacturing deals have pushed shares to an all-time high, but not all earnings are flowing to common stockholders.

Seeking Alpha - 8 months ago

Catalent, Inc. (CTLT) CEO John Chiminski on Q3 2020 Results - Earnings Call Transcript

The Motley Fool - 8 months ago

It helps that the current fiscal year concludes at the end of June, but the business also remains an essential partner for the pharmaceutical industry.

The Motley Fool - 8 months ago

Around 70 companies are working on coronavirus treatments. Here are a few with the most promise.

Other stocks mentioned: BNTX, GILD, GSK, JNJ, MRNA, PFE, VIR

About CTLT

Catalent, together with its subsidiaries, provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, ... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Jul 31, 2014
CEO
John R. Chiminski
Employees
13,900
Stock Exchange
NYSE
Ticker Symbol
CTLT
Full Company Profile

Financial Performance

In 2020, Catalent's revenue was $3.09 billion, an increase of 22.89% compared to the previous year's $2.52 billion. Earnings were $220.70 million, an increase of 60.63%.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for Catalent stock is "Strong Buy." The 12-month stock price forecast is 114.90, which is a decrease of -2.86% from the latest price.

Price Target
$114.90
(-2.86% downside)
Analyst Consensus: Strong Buy